These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 31425946)
1. Urinary podocyte-associated mRNA profile in Egyptian patients with diabetic nephropathy. Fayed A; Rahman Tohamy IA; Kahla H; Elsayed NM; El Ansary M; Saadi G Diabetes Metab Syndr; 2019; 13(5):2849-2854. PubMed ID: 31425946 [TBL] [Abstract][Full Text] [Related]
2. Urinary podocyte-associated mRNA profile in various stages of diabetic nephropathy. Zheng M; Lv LL; Ni J; Ni HF; Li Q; Ma KL; Liu BC PLoS One; 2011; 6(5):e20431. PubMed ID: 21655212 [TBL] [Abstract][Full Text] [Related]
3. Increased Urinary Excretion of Podocyte Markers in Normoalbuminuric Patients with Diabetes. Lioudaki E; Stylianou KG; Petrakis I; Kokologiannakis G; Passam A; Mikhailidis DP; Daphnis EK; Ganotakis ES Nephron; 2015; 131(1):34-42. PubMed ID: 26340089 [TBL] [Abstract][Full Text] [Related]
4. Messenger RNA expression of podocyte-associated molecules in the urinary sediment of patients with diabetic nephropathy. Wang G; Lai FM; Lai KB; Chow KM; Li KT; Szeto CC Nephron Clin Pract; 2007; 106(4):c169-79. PubMed ID: 17596726 [TBL] [Abstract][Full Text] [Related]
5. Role of urinary podocalyxin in early diagnosis of diabetic nephropathy. Kostovska I; Trajkovska KT; Cekovska S; Topuzovska S; Kavrakova JB; Spasovski G; Kostovski O; Labudovic D Rom J Intern Med; 2020 Dec; 58(4):233-241. PubMed ID: 32780718 [No Abstract] [Full Text] [Related]
6. Urinary podocyte mRNAs precede microalbuminuria as a progression risk marker in human type 2 diabetic nephropathy. Fukuda A; Minakawa A; Kikuchi M; Sato Y; Nagatomo M; Nakamura S; Mizoguchi T; Fukunaga N; Shibata H; Naik AS; Wiggins RC; Fujimoto S Sci Rep; 2020 Oct; 10(1):18209. PubMed ID: 33097787 [TBL] [Abstract][Full Text] [Related]
7. Urinary podocalyxin is an early marker for podocyte injury in patients with diabetes: establishment of a highly sensitive ELISA to detect urinary podocalyxin. Hara M; Yamagata K; Tomino Y; Saito A; Hirayama Y; Ogasawara S; Kurosawa H; Sekine S; Yan K Diabetologia; 2012 Nov; 55(11):2913-9. PubMed ID: 22854890 [TBL] [Abstract][Full Text] [Related]
8. Urinary mRNA markers of epithelial-mesenchymal transition correlate with progression of diabetic nephropathy. Zheng M; Lv LL; Cao YH; Zhang JD; Wu M; Ma KL; Phillips AO; Liu BC Clin Endocrinol (Oxf); 2012 May; 76(5):657-64. PubMed ID: 21824169 [TBL] [Abstract][Full Text] [Related]
9. Messenger RNA levels of podocyte-associated proteins in subjects with different degrees of glucose tolerance with or without nephropathy. do Nascimento JF; Canani LH; Gerchman F; Rodrigues PG; Joelsons G; dos Santos M; Pereira S; Veronese FV BMC Nephrol; 2013 Oct; 14():214. PubMed ID: 24103534 [TBL] [Abstract][Full Text] [Related]
10. Saxagliptin attenuates glomerular podocyte injury by increasing the expression of renal nephrin and podocin in type 2 diabetic rats. Hu Y; Ye S; Xing Y; Lv L; Hu W; Zhou W Acta Diabetol; 2020 Mar; 57(3):279-286. PubMed ID: 31535208 [TBL] [Abstract][Full Text] [Related]
11. Intra-renal and urinary mRNA expression of podocyte-associated molecules for the estimation of glomerular podocyte loss. Wang G; Lai FM; Lai KB; Chow KM; Kwan BC; Li KT; Szeto CC Ren Fail; 2010 Jan; 32(3):372-9. PubMed ID: 20370455 [TBL] [Abstract][Full Text] [Related]
12. Urinary Exosomal mRNA of WT1 as Diagnostic and Prognostic Biomarker for Diabetic Nephropathy. Abe H; Sakurai A; Ono H; Hayashi S; Yoshimoto S; Ochi A; Ueda S; Nishimura K; Shibata E; Tamaki M; Kishi F; Kishi S; Murakami T; Nagai K; Doi T J Med Invest; 2018; 65(3.4):208-215. PubMed ID: 30282862 [TBL] [Abstract][Full Text] [Related]
13. Urinary podocyte stress marker as a prognostic indicator for diabetic kidney disease. Zeng L; Ng JK; Fung WW; Chan GC; Chow KM; Szeto CC BMC Nephrol; 2024 Jan; 25(1):32. PubMed ID: 38267859 [TBL] [Abstract][Full Text] [Related]
14. A pilot trial assessing urinary gene expression profiling with an mRNA array for diabetic nephropathy. Zheng M; Lv LL; Cao YH; Liu H; Ni J; Dai HY; Liu D; Lei XD; Liu BC PLoS One; 2012; 7(5):e34824. PubMed ID: 22629296 [TBL] [Abstract][Full Text] [Related]
15. Urinary podocalyxin levels were associated with urinary albumin levels among patients with diabetes. Shoji M; Kobayashi K; Takemoto M; Sato Y; Yokote K Biomarkers; 2016; 21(2):164-7. PubMed ID: 26635084 [TBL] [Abstract][Full Text] [Related]
16. Expression patterns of podocyte-associated mRNAs in patients with proliferative or non-proliferative glomerulopathies. Rodrigues PG; Bringhenti RN; do Nascimento JF; Joelsons G; dos Santos M; Pereira S; Veronese FV Int J Clin Exp Pathol; 2014; 7(5):2185-98. PubMed ID: 24966927 [TBL] [Abstract][Full Text] [Related]
17. Urine podocyte mRNAs mark progression of renal disease. Sato Y; Wharram BL; Lee SK; Wickman L; Goyal M; Venkatareddy M; Chang JW; Wiggins JE; Lienczewski C; Kretzler M; Wiggins RC J Am Soc Nephrol; 2009 May; 20(5):1041-52. PubMed ID: 19389856 [TBL] [Abstract][Full Text] [Related]
19. Urinary messenger RNA expression of podocyte-associated molecules in patients with diabetic nephropathy treated by angiotensin-converting enzyme inhibitor and angiotensin receptor blocker. Wang G; Lai FM; Lai KB; Chow KM; Kwan BC; Li PK; Szeto CC Eur J Endocrinol; 2008 Mar; 158(3):317-22. PubMed ID: 18299464 [TBL] [Abstract][Full Text] [Related]
20. Urinary podocalyxin positive-element occurs in the early stage of diabetic nephropathy and is correlated with a clinical diagnosis of diabetic nephropathy. Ye H; Bai X; Gao H; Li L; Wu C; Sun X; Zhang C; Shen Y; Zhang J; Lu Z J Diabetes Complications; 2014; 28(1):96-100. PubMed ID: 24075693 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]